Rallybio Corporation

NASDAQ:RLYB

Biotechnology

Healthcare
$15.26 +0.03%

+$0.01 today

Market cap
$82.16M
Beta
-0.88
P/E (TTM)
-11.6
EPS (TTM)
-$1.37
52W Low $2.40High $17.57

Volume 0.03M

Average 0.25M

RLYB Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Rallybio CorporationNASDAQ: RLYB

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $0, compared with $0 a year earlier.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Net Receivables vs competitors

How RLYB compares with its peers on the latest reported figures

  • RLYB's Mar 2026 net receivables of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
  • Net receivables amounts to 0.0% of total assets for RLYB, versus a peer median of 0.0%.
RLYB Competitors Peer median
Net Receivables for RLYB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IBIOiBio, Inc.Jun 2026$1.1M +951.4%+75.6%1.1%
RLYBRallybio CorporationMar 2026$0 ——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 -100.0%—0.0%
BOLDBoundless Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding RLYB) $0+425.7%+75.6%0.0%

Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents175.33M56.96M24.49M13.9M31.37M
Short-term Investments0112.04M85.44M51.61M23.36M
Net Receivables00000
Inventory00000
Other Current Assets395K1.05M2.05M995K2.52M
Total Current Assets180.87M179.5M114.79M67.84M61.25M
Property, Plant & Equipment (Net)511K909K592K267K198K
Goodwill00000
Intangible Assets00000
Long-term Investments805K30K239K00
Tax Assets00000
Other Non-current Assets0000810K
Total Non-current Assets1.32M939K831K267K1.01M
Total Assets182.19M180.44M115.62M68.11M62.26M
Account Payables603K1.11M976K278K126K
Short-term Debt00000
Tax Payables00000
Deferred Revenue000848K212K
Other Current Liabilities2.99M4.7M3.17M3.1M1.46M
Total Current Liabilities6.55M10.74M9.26M6.24M4.22M
Long-term Debt0374K000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000212K0
Other Non-current Liabilities32K(374K)000
Total Non-current Liabilities32K374K173K212K82K
Total Liabilities6.58M11.12M9.44M6.45M4.31M
Common Stock3K4K4K4K4K
Retained Earnings(94.03M)(160.68M)(235.25M)(293.02M)(302M)
Accumulated OCI0(214K)15K68K18K
Other Stockholders Equity00000
Minority Interest00000
Total Equity175.6M169.32M106.18M61.65M57.96M
Total Debt0555K392K154K176K
Net Debt(175.33M)(56.4M)(24.1M)(13.75M)(31.2M)

Rallybio Corporation

NASDAQ:RLYB

Intrinsic Alpha fair value

Locked

Current Price

$15.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.